Tailored treatment tested for tough head and neck cancers
NCT ID NCT04326257
Summary
This study tested a personalized approach for patients with advanced head and neck cancer that had worsened despite prior immunotherapy. Doctors analyzed each patient's tumor to choose a second immunotherapy drug to add to a standard one, aiming to better control the cancer. The goal was to see if this tailored combination could shrink tumors or slow their growth in patients who had run out of other options.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania, 15232, United States
Conditions
Explore the condition pages connected to this study.